53 results about "Vascular endothelial growth factor A" patented technology

The invention belongs to the field of biotechnology-monoclonal antibody. The present invention discloses a monoclonal antibody for antagonistic inhibition of combination of vascular endothelial cell growth factor (VEGF) and a receptor of the VEGF, and a hybridoma cell line secreting the monoclonal antibody, wherein the preservation number of the hybridoma cell line is CGMCC No.5889. The present invention further discloses a preparation method and a use of the monoclonal antibody, wherein the use comprises application of the monoclonal antibody in VEGF protein detection and application of the monoclonal antibody in preparation of a drug preparation for treatment of angiogenesis-related diseases.

The invention provides a carbohydrate composition with a wound healing promoting effect and application of the carbohydrate composition. The carbohydrate composition contains at least five types of carbohydrate including carboxymethyl chitosan, rhizoma bletillae polysaccharides, fucoidan from fucus vesiculosus, heparan sulfate, chondroitin sulfate, oligosaccharides of hyaluronan and gulose aldehyde acid oligosaccharides. The carbohydrate composition and the application have the advantages that VEGFA (vascular endothelial growth factor A), FGF2 (fibroblast growth factor 2) and VE-cadherin protein mRNA (messenger ribonucleic acid) expression can be obviously improved by the carbohydrate composition, VEGF (vascular endothelial growth factor) secretion and skin fibroblast (HSF) and human immortalized keratinocyte (HaCaT) proliferation can be obviously promoted by the carbohydrate composition, and the obvious wound healing promoting effect can be realized by the carbohydrate composition; raw materials required by the carbohydrate composition are easily available, composition methods for the carbohydrate composition are simple, the carbohydrate composition is low in cost, easy to industrialize and wide in application range, and the like.

The invention provides anti-aging agents, angiogenesis inhibitors and vascular endothelial growth factor (VEGF) expression inhibitors containing one or more galenicals selected from the group consisting of mukurossi peel extract, hazelnut extract, linden extract, coix extract, chlorella extract and tormentilla extract.

A precious metal plasma effect enhanced up-conversion fluorescence structure-based method for the hypersensitive detection of a vascular endothelial growth factor relates to the fields of nano-materials and analytical chemistry. A standard curve between the intensity of a fluorescence signal and the concentration of the vascular endothelial growth factor is established through synthesizing up-conversion nano-particles (NaYF4, Yb, Tm) with the particle size of 27.1 nm, synthesizing gold nano-particles with the particle size of 4.6 nm, modifying the up-conversion nano-particles, wrapping the gold nano-particles, carrying out single-strand DNA modification on the up-conversion nano-particles, carrying out single-strand DNA modification on the surface of the gold nano-particles, serially regulating a spacing between the particles, and carrying out enhanced regulation and intensity detection on the up-conversion fluorescence signal. Compared with traditional detection methods, the fluorescence enhanced signal-based method for detecting the vascular endothelial growth factor has the advantages of low background, high sensitivity, convenience, fastness and very good practical application prospect.

The invention discloses a latex-enhanced immunoturbidimetric kit for a vascular endothelial growth factor and an application of the kit. The kit comprises a reagent R1, a reagent R2 and a vascular endothelial growth factor calibrator, wherein the reagent R1 includes 3-(N-morpholinyl)propanesulfonic acid buffer, polyethylene glycol p-isooctyl phenyl ether, BSA, glycine, a surfactant and an antiseptic, and the reagent R2 comprises a phosphate buffer, latex microspheres coated with a vascular endothelial growth factor antibody, BSA, a surfactant, trehalose, mannitol, sucrose, PEG 6000, and an antiseptic. The kit allows a Fc segment of a VEFG antibody to be coupled with polystyrene latex particles through a directional coupling method. The coating effect is good, the antibody is not easy to beseparated from latex particles, and the utilization rate and detection sensitivity of the antibody are greatly improved.

The invention discloses an anti-human vascular endothelial growth factor (VEGFA) antibody, a preparation method and an application thereof. The heavy chain variable region of the VEGFA antibody comprises one or more of CDR1, CDR2 and CDR3, and an amino acid sequence and a nucleic acid sequence thereof are as described in the present invention respectively. the VEGFA antibody has high affinity andhigh biological activity, can be better combined with VEGF, and inhibit or block the binding of VEGF and VEGFR, so that a subsequent signal pathway and corresponding biological functions can be influenced, and the anti-human vascular endothelial growth factor can be well applied in anti-tumor, age-related macular degeneration, diabetic retinopathy, chronic eczema, rheumatoid arthritis and chronicinflammation.

The invention discloses application of RIPK4 as a target site in preparing urinary bladder carcinoma treating medicine. Researches show that RIPK4 in BUC is obviously improved, expression induction ofthe RIPK4 is excessive, and silent RIPK4 can inhibit in-vitro and in-vivo BUC invasion and metastasis. Therefore, the RIPK4 can serve as the target site to be applied to preparing urinary bladder carcinoma treating medicine. In addition, the condition RIPK4 up-regulation can cause vascular endothelial growth factor A (VEGF-A) level increasing is proved, so that the RIPK4 can be applied to preparing target negative regulation VEGF-A expression preparation. Meanwhile, VEGF-A can serve as a target site to be applied to preparing the urinary bladder carcinoma treating medicine.

A non-cell active derminal matrix used for skin transplanting contains the derminal matrix containing basically no cells and the cell factor chosen from fibroblast growth factor, vascular endothelial growth factor, platelet derived growth factor, transforming growth factor-alpha, or their mixture. Its advantages are high successful rate of skin transplantation and high transplant effect.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The invention discloses a gene medicine for preventing and treating neovascular eye diseases. The invention relates to the technical field of gene medicines, in particular to a recombinant vector which comprises a PEDF or PEDF functional fragment gene and a shRNA fragment targeting human VEGFA (vascular endothelial growth factor A). The invention also provides application of the recombinant vector in preparation of medicines for preventing or treating angiogenesis-related eye diseases. The PEDF overexpression and VEGFA interference adeno-associated virus involved in the invention can interfere with the expression level of the VEGFA in vascular endothelial cells, effectively down-regulate the protein level of the VEGFA, further inhibit the proliferation and migration activity of the vascular endothelial cells, and inhibit the angiogenesis ability of the vascular endothelial cells, so that a new target and approach for the treatment of wet maculopathy is provided.

The invention discloses a monoclonal antibody, a composition taking same as an active ingredient, and application of the monoclonal antibody. The monoclonal antibody is a novel vascular endothelial growth factor A (VEGF-A) resistant human ScFv-Fc gene engineering antibody; the total molecular formula of the antibody is C2156H3272N561O681S12, and the molecular weight is 46KD; and the antibody is characterized in that: a full human antibody molecule specific to VEGF-A and capable of bonding with the VEGF-A in high affinity can be used for treating choroidal neovascularization (CNV) eye diseases. The monoclonal antibody can be widely applied and brings great social and economic benefits.

The invention relates to a CTL (cytotoxic lymphocyte) epitope polypeptide of vascular endothelial growth factors and application of the CTL epitope polypeptide. Amino acid sequences of the CTL epitope polypeptide are shown as SEQ ID NO.3; a derivative sequence or a plurality of derivative sequences of amino acid is substituted, deleted, displaced, inserted and/or added to the CTL epitope polypeptide on the basis of the amino acid sequences show as the SEQ ID NO.3. The invention further provides vaccine. The vaccine comprises the CTL epitope polypeptide of the vascular endothelial growth factors and an adjuvant. The adjuvant is gp96 protein. The CTL epitope polypeptide, the application and the vaccine have the advantages that the adjuvant and the CTL epitope polypeptide of the vascular endothelial growth factors are matched with each other, accordingly, the immunity can be improved, tumor treatment effects can be obviously improved, and the like.

Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.

The invention discloses a HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on VEGFA and application thereof, the model comprises a line chart used for evaluating chemotherapy curative effect, scores corresponding to four indexes BMI, Diagnose Pattern, VEGFA and CA19-9 in the first row from the second row to the fifth row are added to obtain a total score of a sixth row of patients, and the total score of the sixth row of patients is calculated to obtain the first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect. And correspondingly projecting the total score of the patient in the sixth row to the seventh row to obtain the probability that the treatment of the patient is invalid. The curative effect prediction line diagram integrating serum VEGFA and common baseline characteristics is simple, clear, popular and easy to understand, and clinical doctors and patients can conveniently perform operation to predict the curative effect. Meanwhile, a satisfactory prediction result is displayed by a curative effect line diagram, clinical judgment and layering can be better guided, and certain help is provided for treatment of HER2 negative advanced gastric cancer patients in the future.